This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a prospective randomised double blinded controlled trial. The study was multi-centred with 176 centres in 10 countries (Canada, the USA, South America and Europe). Follow-up was for 30 days. Patients were randomly assigned to the 2 groups but the method of randomisation was not reported. At least 1 dose of the study drug was administered to 98% of the sample and treatment was prematurely discontinued in 367 patients (11.6% of the sample). 207 of these (13.2%) were in the control group and 160 (10.0%) were in the intervention group. Blinding was achieved by giving all patients a subcutaneous injection at 12 hourly intervals, either of the study drug or a placebo, and an intravenous bolus and continuous infusion of either the study drug or a placebo. Dummy adjustments were also administered to aid in blinding. Diagnosis of outcomes was by predetermined protocols. The end points of the study were verified by a committee who were blinded to the treatments given. The median duration of therapy for both treatment groups was 2.6 days (2.3 days for US patients).
Analysis of effectiveness
The analysis was based on intention to treat. The primary outcome was the composite triple endpoint of death, myocardial infarction (or reinfarction), and recurrent angina by 14 days follow-up. A secondary outcome was the same endpoint at 48 hours and 30 days follow-up. The 3 outcomes were also recorded individually. The incidence of major and minor haemorrhage (an adverse effect of treatment) was also recorded. Groups were statistically comparable in terms of age, weight, sex, family history, smoking and other risk factors and previous cardiac history. Comparisons of the two study groups with adjustment for differences in country of origin were performed using a logistic-regression model.
Effectiveness results
At 14 days the composite outcome of death, myocardial infarction or recurrent angina had occurred in 309 patients (19.8%) in the unfractionated heparin group and in 266 (16.6%) of the enoxaparin group. This was a statistically significant difference (p=0.019, odds ratio 0.80, 95% CI: 0.67 -0.96). At 48 hours, differences were not significant. Death, myocardial infarction or recurrent angina had occurred in 115 (7.4%) in the control and 99 (6.2%) in the intervention group, (p=0.18, OR 0.83, 95 % CI: 0.62 -1.09). At 30 days there was a statistically significant difference. Death, myocardial infarction or recurrent angina had occurred in 364 (23.3%) of the control group and 318 (19.8%) of the intervention group (p=0.016, odds ratio 0.81, 95% CI: 0.68 -0.96). There was no significant difference between groups in serious haemorrhagic complications at 30 days although there was a difference in minor haemorrhages. 107 (7.0%) suffered major haemorrhage in the control group and 102 (6.5%) in the intervention group (p=0.57). 110 (7.2%) suffered minor haemorrhage in the control group and 188 (11.9%) in the intervention group (p<0.001).
Clinical conclusions
Enoxaparin plus aspirin was more effective than unfractionated heparin plus aspirin in reducing the incidence of ischemic events in patients with unstable angina at the expense of an increase of minor bleeding but not of major haemorrhagic events.
Measure of benefits used in the economic analysis
The benefit measure was the reduction of the composite outcome of death, myocardial infarction or recurrent angina after 30 days.
Direct costs
Costs were not discounted due to the short time frame of the study. Quantities and costs were analysed separately. Cost analysis was based on a subset of study patients (936) who were treated in the USA. Complete hospital billing data covering the 30 day follow-up period was available for 655 patients. For these patients hospital charges were converted to hospital costs by using the department level correction factors contained in each hospital's annual Medicare Cost Report. Physicians' fees for the 1995 Medicare fee schedule were used and covered the following services: daily followup in both the intensive care unit and non-ICU, cardiac catheterization, coronary angioplasty and coronary bypass surgery.
